Anavex Life Sciences Corp. Common Stock (AVXL) Stock
NASDAQ · AVXL
2.36
Fundamentals
Market cap
$220.62M
Price / Earnings ratio
-16.7x
Price / Sales ratio
N/A
Price / Book ratio
1.9x
Return on assets
-29.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Business Wire
Rosen Law Firm Encourages Anavex Life Sciences Corp. Investors to Inquire About Securities Class Action Investigation
NeutralAVXLSeptember 20, 2026
Business WireNeutral
Rosen Law Firm Encourages Anavex Life Sciences Corp. Investors to Inquire About Securities Class Action Investigation
AVXL

Stocktwits
AVXL Stock Tanks After Anavex Withdraws EU Bid For Alzheimer's Drug
NeutralAVXLMarch 25, 2026
StocktwitsNeutral
AVXL Stock Tanks After Anavex Withdraws EU Bid For Alzheimer's Drug
AVXL

Stocktwits
AVXL Stock Soars After Anavex’s New Data Suggests Its Alzheimer’s Drug May Slow Brain Shrinkage
NeutralAVXLMarch 23, 2026
StocktwitsNeutral
AVXL Stock Soars After Anavex’s New Data Suggests Its Alzheimer’s Drug May Slow Brain Shrinkage
AVXL

Zacks Investment Research
Anavex Life Sciences (AVXL) Upgraded to Buy: Here's What You Should Know
NeutralAVXLFebruary 12, 2026
Zacks Investment ResearchNeutral
Anavex Life Sciences (AVXL) Upgraded to Buy: Here's What You Should Know
AVXL
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy0
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
125M82M41M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-46.4M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Business Wire
Rosen Law Firm Encourages Anavex Life Sciences Corp. Investors to Inquire About Securities Class Action Investigation
NeutralAVXLSeptember 20, 2026
Business WireNeutral
Rosen Law Firm Encourages Anavex Life Sciences Corp. Investors to Inquire About Securities Class Action Investigation
AVXL

Stocktwits
AVXL Stock Tanks After Anavex Withdraws EU Bid For Alzheimer's Drug
NeutralAVXLMarch 25, 2026
StocktwitsNeutral
AVXL Stock Tanks After Anavex Withdraws EU Bid For Alzheimer's Drug
AVXL

Stocktwits
AVXL Stock Soars After Anavex’s New Data Suggests Its Alzheimer’s Drug May Slow Brain Shrinkage
NeutralAVXLMarch 23, 2026
StocktwitsNeutral
AVXL Stock Soars After Anavex’s New Data Suggests Its Alzheimer’s Drug May Slow Brain Shrinkage
AVXL

Zacks Investment Research
Anavex Life Sciences (AVXL) Upgraded to Buy: Here's What You Should Know
NeutralAVXLFebruary 12, 2026
Zacks Investment ResearchNeutral
Anavex Life Sciences (AVXL) Upgraded to Buy: Here's What You Should Know
AVXL

Zacks Investment Research
Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year?
NeutralAVXLFebruary 12, 2026
Zacks Investment ResearchNeutral
Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year?
AVXL

Stocktwits
Anavex Stock Slides After Hours On EMA Panel’s Negative Alzheimer’s Drug Opinion — Retail Traders Talk Buyout Potential
NeutralAVXLDecember 12, 2025
StocktwitsNeutral
Anavex Stock Slides After Hours On EMA Panel’s Negative Alzheimer’s Drug Opinion — Retail Traders Talk Buyout Potential
AVXL

Stocktwits
AVXL Stock Jumps On Lower Q4 Loss, Anticipation For EMA Approval Of Alzheimer’s Drug
NeutralAVXLNovember 25, 2025
StocktwitsNeutral
AVXL Stock Jumps On Lower Q4 Loss, Anticipation For EMA Approval Of Alzheimer’s Drug
AVXL

Zacks Investment Research
Best Momentum Stocks to Buy for January 21st
NeutralAVXLJanuary 21, 2025
Zacks Investment ResearchNeutral
Best Momentum Stocks to Buy for January 21st
AVXL

Zacks Investment Research
New Strong Buy Stocks for January 21st
NeutralAVXLJanuary 21, 2025
Zacks Investment ResearchNeutral
New Strong Buy Stocks for January 21st
AVXL

Zacks Investment Research
New Strong Buy Stocks for January 26th
NeutralAVXLJanuary 26, 2024
Zacks Investment ResearchNeutral
New Strong Buy Stocks for January 26th
AVXL
About Anavex Life Sciences Corp. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees34
CEODr. Terrie Kellmeyer Ph.D.
IPO DateAug 2, 2006
HeadquartersNew York, NY
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Sandra Boenisch C.P.A., CGA | Principal Financial Officer & Treasurer | 1981 |
| Dr. Terrie Kellmeyer Ph.D. | Interim Chief Executive Officer | — |
Fundamentals
Valuation
Market cap$220.62M
Price-to-sales ratioN/A
Price-to-book value1.93
Price-earnings ratio-16.70
Return on Equity-31.00%
Return on SalesN/A
Return on Assets-29.00%
PEG ratio0.00
Earnings Per Share
Earnings Per Share$-0.15
Income Statement
Average volume780,088
EBITDA$-34.07M
1 year high (52w)$10.38
1 year low (52w)$2.26
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
0 Wall Street Analyst Ratings
N/A
0% Buy
0% Hold
0% Sell
Target price
$0.00
Est return
0.00%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.7 | +4.4 | -4.2 | -3.2 | ||||||||
| 2022 | -26.1 | -0.7 | +16.9 | -32.0 | +0.7 | +21.5 | -0.4 | -2.9 | +6.9 | +16.0 | -28.9 | +4.4 |
| 2023 | +12.3 | -13.4 | -11.5 | -4.3 | +12.4 | -10.7 | +3.0 | -3.1 | -17.5 | -12.3 | +28.3 | +23.0 |
| 2024 | -1.3 | -16.4 | -3.6 | -27.3 | +10.0 | +5.0 | +65.5 | -8.5 | +4.0 | +21.7 | +38.3 | +15.2 |
| 2025 | -23.7 | -8.4 | +3.7 | +18.5 | -19.1 | +22.0 | +21.1 | -13.9 | -6.1 | -11.5 | -50.5 | -6.8 |
| 2026 | +27.7 | -2.0 | -32.2 | +7.7 | -8.7 | -13.1 | +6.6 | -5.1 | -17.1 |



